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Recognition and management of antibodies 
to human platelet antigens in platelet 
transfusion–refractory patients
R.R. Vassallo
Platelet transfusion refractoriness is a problem for parous and mul-
tiply transfused patients, placing them at higher risk for mor-
bidity and mortality when posttransfusion count increments are 
significantly lower than expected. Although nonimmune causes of 
transfusion refractoriness are very common, HLA alloantibodies are 
the most important of the less frequent immune factors respon-
sible for inadequate count increments. As universal leukoreduc-
tion decreases the occurrence of HLA antibody formation, antibodies 
to human platelet antigens (HPAs), an even less common immune 
factor, may rise proportionately. Carefully matched apheresis 
platelets can substantially improve platelet count increments in 
the setting of HLA and HPA alloantibody-mediated transfusion 
refractoriness. An evidence-based HPA testing strategy is 
described along with the incidence and specificity of HPA anti-
bodies in platelet transfusion refractoriness. Optimal strategies to 
manage patients with HPA or combined HPA and HLA antibod-
ies are presented. Ultimately, close cooperation between ordering 
physicians and the blood provider is critical in choosing the 
correct tests and assuring platelet availability during intensive 
support of these challenging patients. 
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Platelet transfusion refractoriness, defined as inappro-priately low platelet count increments 24 hours after two consecutive ABO-identical transfusions, is de-
clining in frequency after the introduction of near-universal 
leukoreduction.1,2 Its impact is significant, however, because 
refractoriness is independently associated with bleeding 
complications and decreased patient survival.3
Causes of Platelet Transfusion Refractoriness
 Causes of poor posttransfusion platelet count incre-
ments are classified according to the mechanism of platelet 
loss, either from activation or by immune destruction. Al-
most 90 percent of platelet transfusion refractoriness oc-
curs in the setting of shortened survival from accelerated 
platelet activation, which results in transfusion increments 
less than half of those expected 24 hours after transfusion.4 
These conditions include splenomegaly, infection, ampho-
tericin B therapy, disseminated intravascular coagulation, 
bleeding, stem cell transplantation, and posttransplant he-
patic venoocclusive disease or graft-versus-host disease.5,6 
Immune destruction occurs in approximately 25 percent of 
unsuccessful transfusions, most frequently coexisting with 
conditions that shorten platelet circulatory survival.4
 A 1-hour posttransfusion platelet count should be ob-
tained to determine whether immune platelet destruction 
is playing a role in poor 24-hour platelet count increments.7 
Because antibody-mediated destruction occurs rapidly, 
platelet recovery less than half of that expected within 1 
hour of transfusion suggests an immunologic component to 
platelet transfusion refractoriness. Yankee et al.8  elegantly 
demonstrated that immune-based platelet transfusion re-
fractoriness is mediated primarily by alloantibodies to HLA 
class I determinants present on the platelet surface. Alloan-
tibodies to human platelet antigens (HPAs) are an impor-
tant but less common cause of immune platelet transfusion 
refractoriness.1,6,9 Transfused platelet destruction by HLA 
and HPA alloantibodies is potentially avoidable by the use 
of products from appropriately matched donors. Immune 
destruction caused by drug-dependent platelet antibod-
ies is quite uncommon and the subject of another review 
in this issue of Immunohematology.10 Panreactive platelet 
autoantibodies may also result in platelet transfusion re-
fractoriness. The diagnosis of autoimmune platelet destruc-
tion is generally known before treatments that predictably 
worsen patients’ baseline thrombocytopenia are initiated. 
As we will see, however, transient de novo production of 
autoantibodies may be observed with exquisitely sensitive 
techniques in a significant percentage of platelet transfu-
sion-refractory individuals. The clinical impact of transient 
autoantibodies appears to be minimal. Lastly, because ABO 
determinants are present on the platelet surface, patients 
with very high isoantibody titers can destroy up to 40 per-
cent of major-mismatched platelets (e.g., group A platelets 
in group O recipients) and thus benefit from ABO-identical 
transfusions.11 Taking this into account, the classic defini-
tion of platelet transfusion refractoriness assumes that 
ABO-identical platelets have already been tried without 
success in improving count increments.
Matched Platelet Strategies
 Cellular product leukoreduction has been shown to re-
duce the incidence of HLA alloimmunization by more than 
50 percent (from 45% to 17 to 18% in the Trial to Reduce 
Alloimmunization to Platelets [TRAP] study).9 Despite 
the mitigating effect of near-universal leukoreduction on 
anti-HLA-mediated platelet transfusion refractoriness, 
approximately 5 percent of patients undergoing high-dose 
chemotherapy or stem cell transplantation still require 
matched platelets to achieve acceptable posttransfusion 
platelet count increments.2 Several methods have been 
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developed to provide HLA-matched platelets. These include 
(1) transfusing platelets from donors with the same HLA-A 
and -B antigens as the recipient (or least-incompatible mis-
matches inferred from known antigenic cross-reactivity or 
lists of immunogenic epitopes present on donor and recipi-
ent HLA antigens), (2) providing antigen-negative prod-
ucts that honor patients’ HLA antibody specificities, or (3) 
crossmatching recipient serum with donor platelets. Each of 
these approaches has strengths and weaknesses, described 
in detail elsewhere.1,6
 Most matching algorithms for platelet transfusion-
refractory patients, in recognition of the preeminent role 
of HLA antibodies, begin with the documentation of HLA 
antibodies with a screening assay. Anti-HLA is detected ap-
proximately 15 to 40 percent of the time (dependent on the 
vigor with which referring physicians have documented im-
mune causes of transfusion refractoriness with 1-hour post-
transfusion counts and the sensitivity of the HLA antibody 
detection assay).12 In the setting of poor 1-hour posttrans-
fusion platelet increments, the likelihood of missed HLA 
antibodies (from nascent IgM antibodies in an IgG-only 
detection system or noncytotoxic antibodies in antiquated 
assays) or the unusual presence of lone HPA antibodies 
rises. Additional testing to search for missed HLA (i.e., 
more-sensitive testing) or as-yet-unsought HPA antibodies 
is usually recommended.
 The other circumstance necessitating further testing is 
the failure of HLA-matched platelet support. Regardless of 
how HLA-matched platelets are chosen, 25 to 50 percent 
of these platelet units do not result in acceptable incre-
ments even 1 hour after the transfusion.13 Even a perfectly 
matched platelet unit is not guaranteed to maintain the 
platelet count in an acceptable range for 24 hours as these 
patients often have comorbidities that shorten platelet cir-
culatory survival. Teasing out whether poor responses to 
matched platelets are caused by suboptimal platelet match-
ing, worsening patient illness, or the development of new 
antibody specificities has important consequences for on-
going platelet transfusion support. Subjecting the patient 
to 1-hour posttransfusion platelet counts after each transfu-
sion is mandatory in this setting to determine whether im-
mune destruction is accounting for disappointing 24-hour 
posttransfusion results. A reexamination of the quality of 
HLA-matching is required. Approximately 60 to 80 per-
cent of matched platelets supplied using only the recipi-
ent’s HLA type (i.e., the HLA antibody screen is reactive, 
but antibody specificities have not been determined) will be 
best-guess mismatches.1 The determination of what HLA 
antibody specificities are actually present can explain the 
failure of many of these units and often results in dramati-
cally better results when antigen-antibody mismatches are 
avoided. Even when the antigen-negative approach is used, 
it is recognized that approximately 10 to 15 percent of pa-
tients broaden their anti-HLA repertoire with time, adding 
new specificities to those likely to produce poor platelet 
count increments.14 If several weeks have passed since the 
last HLA antibody identification test, it should be repeated. 
When HLA-identical or correctly matched antigen-negative 
platelet transfusions have failed, in the absence of dramatic 
worsening of the patient’s clinical status (e.g., new-onset 
septic shock), testing for HPA antibodies is necessary.
Human Platelet Antigens
 Human platelet antigen typing and antibody determi-
nation are described in detail in the accompanying review in 
this issue of Immunohematology.15 All but one of the char-
acterized HPAs represent single nucleotide polymorphisms 
resulting in a lone amino acid change in one of four platelet 
surface glycoproteins (GPs). These include the platelet inte-
grins GP IIb-IIIa and GP Ia-IIa, the platelet von Willebrand 
receptor (GP Ib-IX-V), and CD109 (a GPI-linked cell-cell 
interaction mediator). Genetic susceptibility is known to 
play a role in HPA alloimmunization during pregnancy or 
after transfusion, so only a portion of antigen-negative in-
dividuals are capable of forming antibodies on alloexposure 
to common antigens.16,17 Antibodies have been reported to 
11 antigens residing on these GPs with phenotypic frequen-
cies in Caucasian blood donors between 13 percent and 
100 percent (Table 1).18 These have the potential to result 
in poor responses in a similar percentage of platelet trans-
fusions given the right combination of transfused platelet 
antigen density, recipient antibody titer to avidity, and re-
cipient reticuloendothelial system appetite for antibody-
coated platelets. Another 11 formally recognized HPAs are 
low-frequency antigens (<1%) against which antibodies are 
problematic only in pregnancy when the fetus carries the 
father’s rare immunizing antigen.18 In the setting of platelet 
transfusion, low-frequency antigens would hardly ever be 
encountered and are thus highly unlikely to result in platelet 
transfusion refractoriness.
Table 1. Human platelet antigens (HPA) with Caucasian phenotypic 











HPA-1a PlA1 GP IIIa 98%
HPA-1b PlA2 GP IIIa 29%
HPA-2a Kob GP Ibα >99%
HPA-2b Koa GP Ibα 13%
HPA-3a Baka GP IIb 81%
HPA-3b Bakb GP IIb 70%
HPA-4a Pena/Yukb GP IIIa >99%
HPA-5a Brb GP Ia 99%
HPA-5b Bra GP Ia 20%
HPA-15a Govb CD109 74%
HPA-15b Gova CD109 81%
 *From Norton et al.18
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HPAs in platelet transfusion refractoriness
 Approximately 0.5 percent of Asian Americans and Af-
rican Americans lack CD36 (a widely distributed scavenger 
receptor known on platelets as GP IV) on cells throughout 
the body.19 They are at risk for isoimmunization to the so-
called Naka antigen on alloexposure by pregnancy or trans-
fusion. Another 4.5 percent of individuals from these same 
ethnic groups lack CD36 on their platelets (but express it 
elsewhere) and unlike Caucasians, who almost uniformly 
express CD36 on platelets, can serve as donors for im-
munized patients.
 Table 2 shows the incidence of HPA antibodies in pa-
tients tested for the development of HLA and HPA antibod-
ies after intensive episodes of transfusion. Several points 
deserve emphasis. The literature is divided regarding the 
appearance of HPA antibodies after transfusion. In studies 
testing only once or twice, the prevalence of HPA antibod-
ies is relatively low (4.5%; range, 0–13.6%), whereas the 
prevalence reported with weekly testing is higher (13.8%; 
range, 3.9–47.5%).20–28 In the study with the highest re-
ported prevalence, 70 percent of incident antibodies ap-
peared during infection and lasted no more than 300 days, 
with a mean persistence of less than a month for partici-
pants monitored for up to 70 days.27 Half of these antibod-
ies were reactive with autologous platelets, and the authors 
were unable to discern any effect of transient anti-platelet 
antibodies on platelet increments. The assay technology 
used in this study also may not have clearly distinguished 
HPA from HLA antibodies, and there was only rudimentary 
estimation of the breadth of alloimmunization (using only 
four cells). Removing this study’s unusually high number of 
HPA antibodies, overall estimates for HPA antibody forma-
tion become more uniform, averaging just under 5 percent, 
with approximately 16 percent of alloimmunized patients 
manifesting HPA antibodies. This 5 percent figure derived 
from the study of almost 1200 patients with various diag-
noses is somewhat lower than the TRAP trial’s report of an 
8 percent incidence of HPA antibodies among its 530 pa-
tients with acute leukemia.9
 Although older literature suggests that HPA antibod-
ies only rarely lead to significant refractoriness and that 
most instances of platelet transfusion refractoriness are 
limited to case reports, just over 3 percent of the patients 
our matching service supports annually have clinically sig-
nificant HPA antibodies.27,29 This is lower than the expect-
ed overall anti-HPA detection rate of 5 percent. Our lower 
value of clinically significant HPA antibodies is not entirely 
unexpected for two reasons. First, it is well known that less 
than half of HLA alloantibodies cause strictly defined plate-
let transfusion refractoriness (e.g., in the TRAP study, 17–
18% of patients receiving leukoreduced products exhibited 
HLA antibodies, but only 3–4% had alloimmune transfu-
sion refractoriness within the overall rate of refractoriness 
of 7–8%).6,9 Some antibodies may not be potent enough or 
find enough targets on the platelet surface to bind in signifi-
cant numbers, some recipients may not be able to rapidly 
destroy antibody-coated platelets, and the definition of re-
fractoriness considers immediate destruction of less than 
half of transfused platelets as clinically insignificant. It is 
not surprising that HPA antibodies would react similarly. 
Second, the breadth of alloimmunization affects the likeli-
hood that clinical transfusion refractoriness will result. For 
our matching service, the median fraction of units predicted 
to carry antigens incompatible with patients’ HLA antibod-
ies is approximately 65 percent. As will be demonstrated, 
the corresponding value for our patients’ HPA antibodies is 
less than half that. Thus, whereas HPA antibodies are prob-
ably less likely to result in clinical transfusion refractoriness 
than HLA antibodies, their clinical impact is not negligible 
and they are not particularly rare.
Table 2. Prevalence of HPA antibodies*
A. Single determination per patient, only identifiable HPA specificities 
counted
HPA only HPA+HLA HLA only Patients Reference
1 1 21 117 Taaning et 
al.20
5 15 93 252 Kiefel et al.21
0 6 58 293 Kickler et 
al.22
0 3 12 145 Legler et 
al.23
7 4 32 81 Kurz et al.24
0 0 11 50 Godeau et 
al.25
13 (1.4%) 29 (3.1%) 227 (24.2%) 938






8 2 22 104 Uhrynowska et al.26
18 10 9 59 McGrath et al.27
2 4 55 154 Murphy et al.28
28 
(8.8%)
16 (5.0%) 86 
(27.1%)
317
*All studies identified HPA antibodies using monoclonal antibody im-
mobilization of platelet antigens (MAIPA) tests or a GP-specific RIA 
except the studies of McGrath et al.27 and Murphy et al.,28 which used 
less-specific testing (comparing platelet immunofluorescence [PIF] 
before and after HLA antigen removal with chloroquine or comparing 
PIF with HLA-dependent lymphocytotoxicity panels). Nonidentifiable 
specificity represents GP reactivity in the MAIPA with platelets bear-
ing different HPA polymorphisms on GP IIb-IIIa, GP Ib/IX/V, or GP 
Ia-IIa.
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Providing HPA-Compatible Platelets
 When patients appear to have immune-mediated plate-
let transfusion refractoriness and either have no identifi-
able HLA antibodies or have had poor platelet increments 
with presumably properly HLA-matched platelets, testing 
for HPA antibodies is indicated. Detection and identifica-
tion of HPA antibody specificities can be carried out with 
relatively rapid commercially available ELISAs. The older 
literature describes ELISAs as less sensitive, recommend-
ing more time-consuming assays such as the gold-standard 
monoclonal antibody immobilization of platelet antigens 
(MAIPA) test (and its variants) or platelet immunofluores-
cence (PIF) assays properly controlled for concurrent HLA 
antibodies.39 More recent international workshops have 
demonstrated relatively equal performance for ELISA and 
the MAIPA, attributed to variability in technique in labo-
ratories using the technically complex MAIPA.40 MAIPA or 
PIF testing is currently the only option to detect HPA-15 an-
tibodies. Detection of CD36 isoantibodies is possible using 
all three of the most commonly performed assays (ELISA, 
MAIPA, and PIF). Because HPA antibody specificity is de-
rived from the pattern of reactivity with cells or wells with 
known HPA antigens, it is helpful to confirm antibody iden-
tity by demonstrating that the recipient’s genotype predicts 
that he or she does not express that particular antigen.
 Most blood suppliers do not have extensive panels of 
HPA-typed apheresis platelet donors. Because HPA-1a is 
the antibody most frequently responsible for neonatal al-
loimmune thrombocytopenia and posttransfusion purpura, 
larger blood centers often screen their apheresis donors to 
identify the approximately 2 percent who are HPA-1a (PlA1)-
negative. Because HPA-1a is not commonly responsible for 
platelet transfusion refractoriness, these donor panels are 
usually not helpful. If a more broadly typed apheresis do-
nor panel is available, choosing one whose HPA (and HLA) 
types avoid the recipient’s antibody specificities is prefer-
able. On-demand donor typing is practical for recipients 
with antibodies to lower-frequency antigens because fewer 
donors require screening. Genotyping is preferred, despite 
rare incorrect phenotypic predictions, because it requires 
a smaller sample volume obtainable from the infectious 
disease testing tubes collected routinely at apheresis do-
nations, which can be scheduled as frequently as every 3 
days. (The limited availability of antisera for phenotyping 
also makes genotyping more practical.) When patients have 
 In the cross-sectional prevalence studies from Table 
2A, more than two thirds of HPA antibodies appear in the 
presence of HLA antibodies. It has been proposed that HLA 
alloimmunization may identify individuals more suscep-
tible to the formation of HPA antibodies.30,31 The additional 
restrictions that HPA antibodies place on HLA-selected 
platelets help explain some of the failures of HLA-identical 
and HLA antigen-negative platelet units. These data also 
support the HPA antibody screening of individuals with-
out apparent HLA antibodies when immune platelet trans-
fusion refractoriness is highly likely in the setting of poor 
1-hour posttransfusion platelet count increments. It should 
be recognized, though, that the fraction of transfusion-
refractory individuals who harbor HPA antibodies in isola-
tion is probably less than 2 percent. Case reports of isolated 
HPA antibodies exist and our matching service sees at least 
one such patient annually, usually with an HPA-1a (PlA1) or 
CD36 (Naka) antibody.32,33
 Table 3 shows the specificities of HPA antibodies iden-
tified in multiply transfused patients. In older studies with 
limited specificity testing, the majority of antibodies are 
directed against HPAs with phenotypic frequencies less 
than 30 percent (i.e., three quarters are directed at HPA-1b, 
HPA-2b, and HPA-5b). All of these studies were conducted 
using technologies unable to identify antibodies to CD109 
or CD36. More recent studies capable of detecting CD109 
antibodies estimate that approximately 30 percent of HPA 
antibodies target CD109, whereas almost 60 percent are 
still directed against antigens with phenotypic frequencies 
less than 30 percent.35,36 Fortunately, for the majority of pa-
tients with HPA antibodies, less than 30 percent of platelet 
transfusions are at risk for inappropriately low increments, 
as noted above.
 The TRAP study demonstrated that leukoreduction had 
no effect on the incidence of HPA alloimmunization.9 This 
is because HLA presentation to recipients’ immune systems 
occurs through transfused donor antigen-presenting cells 
(APCs) and is thus ameliorable through leukoreduction, 
whereas HPA presentation occurs by recipient APCs, which 
would be unaffected by leukoreduction of transfused blood 
components.37,38 Accordingly, although HLA alloimmuniza-
tion is decreasing with the widespread use of leukoreduced 
blood products, HPA alloimmunization will be unaffected 
and could represent an increasing proportion of detected 
alloantibodies as HLA antibodies decline in prevalence.
Table 3. Identified HPA specificities
1a 1b 2a 2b 3a 3b 5a 5b 15a 15b
4 (7.1%)* 18 (32.1%) 1 (1.8%) 6 (10.7%) 4 (7.1%) 3 (5.4%) 2 (3.6%) 18 (32.1%)
5 (6.4%)† 15 (19.2%) 8 (10.3%) 1 (1.3%) 4 (5.1%) 22 (28.2%) 7 (9.0%) 16 (20.5%)
*Composite of references 20–23, 26, 33, 31, and 34 (these studies only assayed antibodies to HPAs 1, 2, 3, and 5).
†Composite of references 35 and 36 (assayed antibodies to HPAs 1, 2, 3, 4, 5, and 15).
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high-frequency antibodies, it is often helpful to begin HPA 
(geno)typing with family members.
 Despite a lack of literature, in the absence of known 
type-compatible donors, platelet crossmatching is often 
used to predict platelet compatibility. Crossmatching is 
most frequently performed using a commercially avail-
able solid-phase RBC adherence (SPRCA) assay. If HLA 
antibodies are concurrently present, only HLA-compatible 
units should be crossmatched. We have observed that re-
sults are more reliable for antibodies directed against HPAs 
with higher platelet surface densities, as greater amounts of 
bound antibody are more likely to identify incompatibility 
in the assay. Table 4 predicts that antibodies to HPAs ex-
pressed on GP IIb-IIIa or Ib-IX-V are more likely to yield 
reliable SPRCA results. All too often, however, units ap-
pearing compatible in vitro fail in vivo, and only after the 
donor’s genotype is obtained days later is the platelet in-
crement failure explained. Donors whose transfused plate-
lets succeed in producing good count increments should 
be called back to donate additional products. With high-
frequency recipient antibodies in the absence of compatible 
donors, crossmatched units with the weakest incompatibil-
ity are preferred by some. There is, however, no evidence 
that decreased in vitro reactivity in any way predicts lim-
ited in vivo platelet destruction. Unfortunately, more ro-
bust crossmatch methods (PIF, MAIPA) are generally too 
onerous to implement routinely. Ultimately, as economical, 
high-throughput HPA genotyping methods come into wide-
spread use, panels of donors pretyped for HPAs 1 through 
5 and 15 will assist in the choice of HPA antigen-negative 
units and obviate the need for crossmatching.
 We have observed impressive successes in broadly 
transfusion-refractory patients when donors are carefully 
chosen to avoid HLA and HPA antigens to which recipients 
are alloimmunized. Close cooperation is required among 
clinicians, the hospital transfusion service, and the blood 
supplier to choose the right products and assure their avail-
ability throughout periods of intensive platelet support.
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